Foundayo, a novel daily oral medication designed to treat type 2 diabetes and facilitate weight loss, became available in United Kingdom pharmacies on Monday. This new treatment option is accessible through private prescription, offering an alternative for individuals who cannot or prefer not to use injectable GLP-1 receptor agonists, commonly known as weight-loss jabs. Pharmacists have expressed optimism about the introduction of Foundayo, anticipating it will be a valuable addition for many patients managing their diabetes and weight. However, alongside the launch, pharmaceutical professionals have raised significant concerns regarding the proliferation of counterfeit and unlicensed versions of GLP-1 medications. These illicit products pose serious health risks to consumers, as they may contain incorrect dosages, harmful ingredients, or lack the active pharmaceutical ingredients altogether. The availability of fake weight-loss tablets has been an escalating issue, and the introduction of a new oral treatment like Foundayo could potentially exacerbate this problem if regulatory oversight and public awareness are not sufficiently robust. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has been actively working to combat the sale of unlicensed and counterfeit medicines, but the online marketplace and illicit distribution channels continue to present challenges. Foundayo's mechanism of action is understood to involve mimicking the effects of naturally occurring hormones that regulate blood sugar and appetite. By stimulating insulin release and slowing gastric emptying, it helps to control blood glucose levels in individuals with type 2 diabetes. Concurrently, these effects contribute to a reduced feeling of hunger and increased satiety, thereby supporting weight management efforts. The daily pill format offers a convenient alternative to weekly or daily injections, potentially improving adherence for some patients. The drug's availability on private prescription means that patients will need to consult with a healthcare professional who can assess their suitability and issue a prescription, with the cost borne by the patient or covered by private health insurance. The broader context of this launch involves the increasing demand for effective diabetes management and weight loss solutions. GLP-1 receptor agonists, both injectable and now increasingly oral, have demonstrated significant efficacy in clinical trials for both conditions, leading to their widespread adoption. The market for these medications is substantial and growing, attracting both legitimate pharmaceutical development and illicit counterfeit operations. The UK's National Health Service (NHS) currently has strict guidelines on prescribing these medications, often reserving them for specific patient groups with a high body mass index (BMI) and related comorbidities, or for those who have not responded to other treatments. The private prescription route for Foundayo allows for broader access, albeit at a personal cost, and highlights the ongoing evolution of diabetes and obesity treatment landscapes.